AI assistant
Sending…
UroGen Pharma Ltd. — Director's Dealing 2024
Mar 20, 2024
32312_dirs_2024-03-20_6444bbce-b8ed-44ed-9bac-2811c580ef56.zip
Director's Dealing
Open in viewerOpens in your device viewer
SEC Form 4 — Statement of Changes in Beneficial Ownership
Issuer: UroGen Pharma Ltd. (URGN)
CIK: 0001668243
Period of Report: 2024-03-18
Reporting Person: Schoenberg Mark (Chief Medical Officer)
Non-Derivative Transactions
| Date | Security | Code | Shares | Price | A/D | Holdings After | Ownership |
|---|---|---|---|---|---|---|---|
| 2024-03-18 | Ordinary Shares | S | 12000 | $14.05 | Disposed | 139437 | Direct |
Footnotes
F1: A portion of the cash receipts will be used for federal income tax purposes
More from UroGen Pharma Ltd.
Annual Report
2026
May 27
Interim / Quarterly Report
2026
May 6
Regulatory Filings
2026
May 6
Proxy Solicitation & Information Statement
2026
Apr 30
Annual Report
2026
Mar 2
Regulatory Filings
2026
Mar 2
Regulatory Filings
2026
Mar 2
Director's Dealing
2026
Feb 27
Director's Dealing
2026
Feb 19
Director's Dealing
2026
Feb 11